Talphera

Talphera R&D Expenses

The Research & Development Expenses of Talphera (TLPH) as of Nov 5, 2026 is 6.03 M USD. In the previous year, Research & Development Expenses was 6.72 M USD — a change of -10.20% (lower).

R&D Expenses

6.03 MUSD

YoY

-10.20%

Last updated:

Research & Development Expenses of Talphera is 2025 6.03 M USD. Research & Development Expenses of Talphera was 2024 6.72 M USD. It decreases by -10.20% lower compared to the previous year.

The Talphera R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
13.14 M USD
Jan 1, 2019
4.66 M USD
Jan 1, 2020
4.02 M USD
Jan 1, 2021
2.44 M USD
Jan 1, 2022
1.69 M USD
Jan 1, 2023
5.55 M USD
Jan 1, 2024
6.72 M USD
Jan 1, 2025
6.03 M USD
The Talphera R&D Expenses history
YEARR&D ExpensesYoY
6.03 MUSD-10.20%
6.72 MUSD+21.13%
5.55 MUSD+227.39%
1.69 MUSD-30.43%
2.44 MUSD-39.38%
4.02 MUSD-13.82%
4.66 MUSD-64.52%
13.14 MUSD-32.31%
19.41 MUSD-9.31%
21.40 MUSD-4.83%
22.49 MUSD-8.29%
24.52 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Talphera Stock analysis

What does Talphera do? Talphera Inc develops and commercializes therapies for medically supervised settings, focusing on nafamostat-based products. The company's Niyad targets regional anticoagulants for dialysis circuits in acute kidney injury and chronic kidney disease patients. LTX-608 is an intravenous formulation for potential treatment of viral infections, ARDS, DIC, and acute pancreatitis. Pre-filled syringes Fedsyra and PFS-02 are also under development. The firm sells these products to hospitals, dialysis centers, and medical facilities requiring specialized therapies in controlled environments. Niyad is designed for use during continuous renal replacement therapy and hemodialysis procedures, primarily targeting healthcare providers in hospital settings and dialysis centers. LTX-608 aims to address viral and inflammatory conditions, with potential buyers including hospitals treating respiratory and coagulation disorders. The pre-filled syringes Fedsyra and PFS-02 serve as delivery systems for these therapies, appealing to medical institutions needing efficient administration solutions. The company's revenue streams come from the sale of Niyad, LTX-608, Fedsyra, and PFS-02 to healthcare providers. Hospitals and dialysis centers are key buyers for Niyad, while LTX-608 targets hospitals managing viral outbreaks and severe inflammatory conditions. Fedsyra and PFS-02 are sold as complementary products to support the delivery of nafamostat therapies, with demand driven by the need for specialized medical treatments in supervised care settings. Talphera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Talphera stock

Research & Development Expenses of Talphera is 6.03 M USD in 2025.

Research & Development Expenses of Talphera changed from 6.72 M USD to 6.03 M USD, representing a -10.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Talphera since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Talphera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Talphera

All Key Metrics — Talphera